Press release Communiqué de presse
Press release Communiqué de presse
January 28, 2019 28 January, 2019
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
January 28, 2019 6:00 a.m. EST
LONDON, ONTARIO – January 28, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present the latest company overview and is invited to participate on the Diabetes Panel at NobleConXV — Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Fla., on Monday January 28th at 11:00 a.m. Eastern Time.
The panel will cover a broad spectrum of interests involving diabetes including the discovery and commercialization of novel diabetes therapeutics and diagnostics, diabetes research, as well as nutrition and awareness. Included on the panel are Dr. Camillo Ricordi, Director of the Diabetes Research Institute; Dr. Michael Castagna, CEO of MannKind Corporation; Steve Perrin, Ph.D., CEO and Founder of Anelixis Therapeutics; William L. Rust, Ph.D., CEO and Founder of Seraxis; Michael Fox of DugalHealth; Martin Beland, VP Marketing and Strategic Development of Inolife Sciences; Steve Glover, CEO of Variant Pharmaceuticals; and Dr. Philip Toleikis, Ph.D., President & CEO of Sernova Corp.
A video webcast of the presentation will be available the following day on the company's website www.sernova.com and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website (http://nobleconference.com) as well as on the new investor portal created by Noble called Channelchek (http://www.channelchek.com).
About Sernova, Corp Sernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For further information contact:
Danny Matthews, Senior Associate Solebury Trout Tel: (646) 378-2928 firstname.lastname@example.org www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray, Corporate Communications Tel: (519) 858-5126 email@example.com www.sernova.com
Ray Matthews & Associates Tel: (604) 818-7778 firstname.lastname@example.org www.raymatthews.ca
Forward-Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.